Fosun Pharmaceutical (02196) subsidiary's drug registration application has been accepted.

Zhtng Cijng APP News, Fosun Pharma (02196) announced that recently, its subsidiary Fosun Kari (Shanghai) Biotech Co., Ltd. (hereinafter referred to as "Fosun Kari") submitted a drug registration application for Breykyo Lensai Injection (project code: FKC889, application category: therapeutic biologics 3.2; hereinafter referred to as "the product") to the National Medical Products Administration. The indication for this application is for the treatment of relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL) in adult patients.